Tim Meyer
蒂姆·迈耶
PhD, FRCP
Professor of Oncology肿瘤学教授
👥Biography 个人简介
Tim Meyer is a leading UK expert in hepatobiliary oncology, pioneering immunotherapy approaches in HCC and cholangiocarcinoma. He leads major UK liver cancer trials and has contributed to the development of checkpoint inhibitor strategies and biomarker research in liver malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Immunotherapy in HCC
Contributed pivotal early clinical trial data on checkpoint inhibitors in HCC, supporting the development of nivolumab and subsequent combination regimens.
Cholangiocarcinoma Systemic Therapy
Led UK trials investigating novel targeted agents and immunotherapy combinations in biliary tract cancers, advancing treatment options for this rare malignancy.
Biomarker Research in Liver Cancer
Conducted translational studies identifying predictive biomarkers for immunotherapy response in HCC and biliary tract cancers.
Representative Works 代表性著作
Nivolumab in advanced hepatocellular carcinoma (CheckMate 040)
Journal of Clinical Oncology (2019)
Demonstrated durable responses with nivolumab combinations in advanced HCC, supporting immunotherapy regulatory approvals.
Immunotherapy and targeted therapy in biliary tract cancers
Lancet Gastroenterology & Hepatology (2021)
Comprehensive review integrating new data on FGFR inhibitors, IDH1 inhibitors, and checkpoint blockade in cholangiocarcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 蒂姆·迈耶 的研究动态
Follow Tim Meyer's research updates
留下邮箱，当我们发布与 Tim Meyer（UCL Cancer Institute, University College London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment